Simulations Plus, Inc. (NASDAQ:SLP) declared a quarterly dividend on Wednesday, July 10th, NASDAQ reports. Investors of record on Thursday, July 25th will be paid a dividend of 0.06 per share by the technology company on Thursday, August 1st. This represents a $0.24 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Wednesday, July 24th.
Simulations Plus has increased its dividend by an average of 6.3% annually over the last three years and has increased its dividend annually for the last 2 consecutive years. Simulations Plus has a dividend payout ratio of 60.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Simulations Plus to earn $0.59 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 40.7%.
Shares of NASDAQ:SLP opened at $31.24 on Friday. Simulations Plus has a twelve month low of $16.70 and a twelve month high of $32.42. The stock has a 50 day simple moving average of $27.05. The firm has a market cap of $514.25 million, a P/E ratio of 66.73 and a beta of -0.38.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings data on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $9.94 million for the quarter, compared to analyst estimates of $9.85 million. Simulations Plus had a return on equity of 24.08% and a net margin of 24.09%. On average, sell-side analysts anticipate that Simulations Plus will post 0.44 EPS for the current fiscal year.
A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. ValuEngine downgraded Zebra Technologies from a “buy” rating to a “hold” rating in a research report on Friday. Finally, BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday.
In related news, Director Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total transaction of $474,895.00. Following the completion of the sale, the director now owns 5,178,083 shares in the company, valued at $132,921,390.61. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 31.57% of the stock is owned by insiders.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Recommended Story: Why do companies issue stock splits?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.